Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 1/2020

19.11.2019 | 2019 SSAT Plenary Presentation

Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett’s Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study

verfasst von: Vinicius J. Campos, Guilherme S. Mazzini, José F. Juchem, Richard R. Gurski

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Immune imbalance and inflammation have been suggested as key factors of Barrett’s esophagus (BE) pathway towards adenocarcinoma. The neutrophil-lymphocyte ratio (NLR) indirectly reflects the relation between innate and adaptive immune systems and has been studied in premalignant conditions as a biomarker for cancer diagnosis. Our aim was to investigate if increasing values of NLR correlated with advancing stages of BE progression to dysplasia and neoplasia.

Methods

We retrospectively analyzed data of patients with biopsies reporting BE between 2013 and 2017 and with a complete blood count within 6 months from the endoscopy, as well as patients with esophageal adenocarcinoma (EAC). NLR was calculated as neutrophil count/lymphocyte count. Cases (n = 113) were classified as non-dysplastic BE (NDBE, n = 72), dysplastic BE (DBE, n = 11) and EAC (n = 30).

Results

NLR progressively increased across groups (NDBE, 1.92 ± 0.7; DBE, 2.92 ± 1.1; EAC 4.54 ± 2.9), with a significant correlation between its increasing value and the presence of dysplasia or neoplasia (r = 0.53, p < 0.001). NLR > 2.27 was able to diagnose EAC with 80% sensitivity and 71% specificity (area under the curve = 0.8).

Conclusion

NLR correlates with advancing stages of BE progression, a finding that reinforces the role of immune imbalance in EAC carcinogenesis and suggests a possible use of this marker for risk stratification on surveillance strategies.
Literatur
1.
Zurück zum Zitat Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am. 2015 Jun 1;44(2):203–31.PubMedPubMedCentralCrossRef Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am. 2015 Jun 1;44(2):203–31.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008 Mar;103(3):788–97.PubMedCrossRef Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008 Mar;103(3):788–97.PubMedCrossRef
3.
Zurück zum Zitat Fitzgerald R.C., Di Pietro M., Ragunath K., Ang Y., Kang J.-Y., Watson P., et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42.CrossRefPubMed Fitzgerald R.C., Di Pietro M., Ragunath K., Ang Y., Kang J.-Y., Watson P., et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42.CrossRefPubMed
4.
Zurück zum Zitat Qiao Y, Hyder A, Bae SJ, Zarin W, O’Neill TJ, Marcon NE, et al. Surveillance in Patients With Barrett’s Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2015 Dec 10;6:e131.PubMedPubMedCentralCrossRef Qiao Y, Hyder A, Bae SJ, Zarin W, O’Neill TJ, Marcon NE, et al. Surveillance in Patients With Barrett’s Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2015 Dec 10;6:e131.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Sami SS, Ragunath K, Iyer PG. Screening for Barrett’s esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol. 2015 Apr;13(4):623–34.PubMedCrossRef Sami SS, Ragunath K, Iyer PG. Screening for Barrett’s esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol. 2015 Apr;13(4):623–34.PubMedCrossRef
6.
Zurück zum Zitat Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74.PubMedCrossRef Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74.PubMedCrossRef
7.
Zurück zum Zitat Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011 Jun 28;105(1):93–103.PubMedPubMedCentralCrossRef Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011 Jun 28;105(1):93–103.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007 Dec;26(3–4):373–400.PubMedCrossRef Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007 Dec;26(3–4):373–400.PubMedCrossRef
9.
Zurück zum Zitat Mohri Y, Tanaka K, Ohi M, Yokoe T, Miki C, Kusunoki M. Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg .2010 Feb;34(2):285–90.PubMedCrossRef Mohri Y, Tanaka K, Ohi M, Yokoe T, Miki C, Kusunoki M. Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg .2010 Feb;34(2):285–90.PubMedCrossRef
10.
Zurück zum Zitat McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg. 1999 Dec;134(12):1325–31; discussion 1331–2.PubMedCrossRef McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg. 1999 Dec;134(12):1325–31; discussion 1331–2.PubMedCrossRef
11.
Zurück zum Zitat Jabłońska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jabłoński J. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp . 2001;49(1):63–9. Jabłońska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jabłoński J. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp . 2001;49(1):63–9.
12.
Zurück zum Zitat Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013 Oct;88(1):218–30.PubMedCrossRef Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013 Oct;88(1):218–30.PubMedCrossRef
13.
Zurück zum Zitat Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, et al. Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg. 2017 Aug;266(2):339–45.PubMedCrossRef Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, et al. Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg. 2017 Aug;266(2):339–45.PubMedCrossRef
14.
Zurück zum Zitat Siewert JR, Stein HJ. Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection. Dis Esophagus. 1996 Jul 1;9(3):173–82. Siewert JR, Stein HJ. Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection. Dis Esophagus. 1996 Jul 1;9(3):173–82.
15.
Zurück zum Zitat Brown J, Sharma P. From Prague to Seattle: Improved Endoscopic Technique and Reporting Improves Outcomes in Patients with Barrett’s Esophagus. Dig Dis Sci. 2016 Jan;61(1):4–5.PubMedCrossRef Brown J, Sharma P. From Prague to Seattle: Improved Endoscopic Technique and Reporting Improves Outcomes in Patients with Barrett’s Esophagus. Dig Dis Sci. 2016 Jan;61(1):4–5.PubMedCrossRef
16.
Zurück zum Zitat El-Serag HB. The epidemic of esophageal adenocarcinoma. Hematol Oncol Clin North Am. 2003 Apr 1;17(2):413–32.CrossRef El-Serag HB. The epidemic of esophageal adenocarcinoma. Hematol Oncol Clin North Am. 2003 Apr 1;17(2):413–32.CrossRef
17.
Zurück zum Zitat Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011 Oct 13;365(15):1375–83.PubMedCrossRef Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011 Oct 13;365(15):1375–83.PubMedCrossRef
18.
Zurück zum Zitat Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang J-Y, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014 Jan;63(1):7–42.CrossRefPubMed Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang J-Y, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014 Jan;63(1):7–42.CrossRefPubMed
19.
Zurück zum Zitat Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010 Feb;10(2):87–101.PubMedPubMedCentralCrossRef Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010 Feb;10(2):87–101.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011 Jul 6;103(13):1049–57.PubMedPubMedCentralCrossRef Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011 Jul 6;103(13):1049–57.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Di Caro S, Cheung WH, Fini L, Keane MG, Theis B, Haidry R, et al. Role of body composition and metabolic profile in Barrett’s oesophagus and progression to cancer. Eur J Gastroenterol Hepatol. 2016 Mar;28(3):251–60.PubMedPubMedCentralCrossRef Di Caro S, Cheung WH, Fini L, Keane MG, Theis B, Haidry R, et al. Role of body composition and metabolic profile in Barrett’s oesophagus and progression to cancer. Eur J Gastroenterol Hepatol. 2016 Mar;28(3):251–60.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011 Mar;140(3):1084–91.CrossRef American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011 Mar;140(3):1084–91.CrossRef
25.
Zurück zum Zitat Chimal-Ramírez GK, Espinoza-Sánchez NA, Fuentes-Pananá EM. Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J Oncol. 2013 Mar 14;2013:835956.PubMedPubMedCentralCrossRef Chimal-Ramírez GK, Espinoza-Sánchez NA, Fuentes-Pananá EM. Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J Oncol. 2013 Mar 14;2013:835956.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006 Jan;6(1):24–37.PubMedCrossRef de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006 Jan;6(1):24–37.PubMedCrossRef
28.
Zurück zum Zitat Pagès F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautès-Fridman C, Fridman W-H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010 Feb 25;29(8):1093–102.PubMedCrossRef Pagès F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautès-Fridman C, Fridman W-H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010 Feb 25;29(8):1093–102.PubMedCrossRef
29.
Zurück zum Zitat Pagès F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018 May 26;391(10135):2128–39.PubMedCrossRef Pagès F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018 May 26;391(10135):2128–39.PubMedCrossRef
30.
Zurück zum Zitat Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012 Mar 15;12(4):298–306.PubMedCrossRef Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012 Mar 15;12(4):298–306.PubMedCrossRef
31.
Zurück zum Zitat Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 Feb 11;340(6):448–54.PubMedCrossRef Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 Feb 11;340(6):448–54.PubMedCrossRef
32.
Zurück zum Zitat Michaud DS, Houseman EA, Marsit CJ, Nelson HH, Wiencke JK, Kelsey KT. Understanding the Role of the Immune System in the Development of Cancer: New Opportunities for Population-Based Research. Cancer Epidemiol Biomarkers Prev. 2015 Dec;24(12):1811–9.PubMedCrossRef Michaud DS, Houseman EA, Marsit CJ, Nelson HH, Wiencke JK, Kelsey KT. Understanding the Role of the Immune System in the Development of Cancer: New Opportunities for Population-Based Research. Cancer Epidemiol Biomarkers Prev. 2015 Dec;24(12):1811–9.PubMedCrossRef
33.
Zurück zum Zitat Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–4.PubMedCrossRef Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–4.PubMedCrossRef
34.
Zurück zum Zitat Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013 Jan;58(1):58–64.PubMedCrossRef Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013 Jan;58(1):58–64.PubMedCrossRef
35.
Zurück zum Zitat Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 Jun;106(6):dju124.PubMedCrossRef Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 Jun;106(6):dju124.PubMedCrossRef
36.
Zurück zum Zitat Fang H-Y, Huang XY, Chien H-T, Chang JT-C, Liao C-T, Huang J-J, et al. Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma. Laryngoscope. 2013 Nov;123(11):2690–9.PubMedCrossRef Fang H-Y, Huang XY, Chien H-T, Chang JT-C, Liao C-T, Huang J-J, et al. Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma. Laryngoscope. 2013 Nov;123(11):2690–9.PubMedCrossRef
37.
Zurück zum Zitat Wang F, He W, Jiang C, Guo G, Ke B, Dai Q, et al. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer. BMC Cancer. 2018 Nov 12;18(1):1102.PubMedPubMedCentralCrossRef Wang F, He W, Jiang C, Guo G, Ke B, Dai Q, et al. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer. BMC Cancer. 2018 Nov 12;18(1):1102.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Ikeguchi M. Glasgow prognostic score and neutrophil-lymphocyte ratio are good prognostic indicators after radical neck dissection for advanced squamous cell carcinoma in the hypopharynx. Langenbecks Arch Surg. 2016 Sep;401(6):861–6.PubMedCrossRef Ikeguchi M. Glasgow prognostic score and neutrophil-lymphocyte ratio are good prognostic indicators after radical neck dissection for advanced squamous cell carcinoma in the hypopharynx. Langenbecks Arch Surg. 2016 Sep;401(6):861–6.PubMedCrossRef
39.
Zurück zum Zitat Chandrasoma PT. Histologic definition of gastro-esophageal reflux disease. Curr Opin Gastroenterol. 2013 Jul;29(4):460–7.PubMedCrossRef Chandrasoma PT. Histologic definition of gastro-esophageal reflux disease. Curr Opin Gastroenterol. 2013 Jul;29(4):460–7.PubMedCrossRef
40.
Zurück zum Zitat Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett’s carcinogenesis. Pathol Res Pract. 2012 May 15;208(5):269–80.PubMedCrossRef Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett’s carcinogenesis. Pathol Res Pract. 2012 May 15;208(5):269–80.PubMedCrossRef
41.
Zurück zum Zitat Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett’s oesophagus. Lancet. 2002 Nov 16;360(9345):1587–9.PubMedCrossRef Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett’s oesophagus. Lancet. 2002 Nov 16;360(9345):1587–9.PubMedCrossRef
42.
Zurück zum Zitat Kavanagh ME, O’Sullivan KE, O’Hanlon C, O’Sullivan JN, Lysaght J, Reynolds JV. The esophagitis to adenocarcinoma sequence; the role of inflammation. Cancer Lett. 2014 Apr 10;345(2):182–9.PubMedCrossRef Kavanagh ME, O’Sullivan KE, O’Hanlon C, O’Sullivan JN, Lysaght J, Reynolds JV. The esophagitis to adenocarcinoma sequence; the role of inflammation. Cancer Lett. 2014 Apr 10;345(2):182–9.PubMedCrossRef
43.
Zurück zum Zitat Kavanagh ME, Conroy MJ, Clarke NE, Gilmartin NT, O’Sullivan KE, Feighery R, et al. Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma. Cancer Lett. 2016 Jan 1;370(1):117–24.PubMedCrossRef Kavanagh ME, Conroy MJ, Clarke NE, Gilmartin NT, O’Sullivan KE, Feighery R, et al. Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma. Cancer Lett. 2016 Jan 1;370(1):117–24.PubMedCrossRef
44.
Zurück zum Zitat Hardikar S, Onstad L, Song X, Wilson AM, Montine TJ, Kratz M, et al. Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett’s esophagus cohort. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2393–403.PubMedPubMedCentralCrossRef Hardikar S, Onstad L, Song X, Wilson AM, Montine TJ, Kratz M, et al. Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett’s esophagus cohort. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2393–403.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Oka M, Attwood SE, Kaul B, Smyrk TC, DeMeester TR. Immunosuppression in patients with Barrett’s esophagus. Surgery. 1992 Jul;112(1):11–7.PubMed Oka M, Attwood SE, Kaul B, Smyrk TC, DeMeester TR. Immunosuppression in patients with Barrett’s esophagus. Surgery. 1992 Jul;112(1):11–7.PubMed
46.
Zurück zum Zitat Ministério da Saúde – Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA). Estimate 2016 – Cancer Incidence in Brazil. Available from: http://www.inca.gov.br. Ministério da Saúde – Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA). Estimate 2016 – Cancer Incidence in Brazil. Available from: http://​www.​inca.​gov.​br.
47.
Zurück zum Zitat Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010 Jul;105(7):1523–30.PubMedCrossRef Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010 Jul;105(7):1523–30.PubMedCrossRef
48.
Zurück zum Zitat Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol. 1988 Feb;19(2):166–78.PubMedCrossRef Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol. 1988 Feb;19(2):166–78.PubMedCrossRef
49.
Zurück zum Zitat Coco DP, Goldblum JR, Hornick JL, Lauwers GY, Montgomery E, Srivastava A, et al. Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol. 2011 Jan;35(1):45–54.PubMedCrossRef Coco DP, Goldblum JR, Hornick JL, Lauwers GY, Montgomery E, Srivastava A, et al. Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol. 2011 Jan;35(1):45–54.PubMedCrossRef
50.
Zurück zum Zitat Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001 Apr;32(4):368–78.PubMedCrossRef Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001 Apr;32(4):368–78.PubMedCrossRef
51.
Zurück zum Zitat Moole H, Patel J, Ahmed Z, Duvvuri A, Vennelaganti S, Moole V, et al. Progression from low-grade dysplasia to malignancy in patients with Barrett’s esophagus diagnosed by two or more pathologists. World J Gastroenterol .2016 Oct 21;22(39):8831–43.PubMedPubMedCentralCrossRef Moole H, Patel J, Ahmed Z, Duvvuri A, Vennelaganti S, Moole V, et al. Progression from low-grade dysplasia to malignancy in patients with Barrett’s esophagus diagnosed by two or more pathologists. World J Gastroenterol .2016 Oct 21;22(39):8831–43.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Sharma P, Falk G, Sampliner R. Reply. Clin Gastroenterol Hepatol. 2006 Nov 1;4(11):1420. Sharma P, Falk G, Sampliner R. Reply. Clin Gastroenterol Hepatol. 2006 Nov 1;4(11):1420.
53.
Zurück zum Zitat Peters FP, Curvers WL, Rosmolen WD, de Vries CE, Ten Kate FJW, Krishnadath KK, et al. Surveillance history of endoscopically treated patients with early Barrett’s neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus. 2008 Apr 22;21(6):475–9.PubMedCrossRef Peters FP, Curvers WL, Rosmolen WD, de Vries CE, Ten Kate FJW, Krishnadath KK, et al. Surveillance history of endoscopically treated patients with early Barrett’s neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus. 2008 Apr 22;21(6):475–9.PubMedCrossRef
54.
Zurück zum Zitat Ryan AM, Healy LA, Power DG, Byrne M, Murphy S, Byrne PJ, et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg. 2008 Jun;247(6):909–15.PubMedCrossRef Ryan AM, Healy LA, Power DG, Byrne M, Murphy S, Byrne PJ, et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg. 2008 Jun;247(6):909–15.PubMedCrossRef
55.
Zurück zum Zitat Zhang S, Zhang X-Q, Ding X-W, Yang R-K, Huang S-L, Kastelein F, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta-analysis. Br J Cancer. 2014 Apr 29;110(9):2378–88.PubMedPubMedCentralCrossRef Zhang S, Zhang X-Q, Ding X-W, Yang R-K, Huang S-L, Kastelein F, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta-analysis. Br J Cancer. 2014 Apr 29;110(9):2378–88.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):456–61.PubMedPubMedCentralCrossRef Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):456–61.PubMedPubMedCentralCrossRef
Metadaten
Titel
Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett’s Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study
verfasst von
Vinicius J. Campos
Guilherme S. Mazzini
José F. Juchem
Richard R. Gurski
Publikationsdatum
19.11.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 1/2020
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04456-x

Weitere Artikel der Ausgabe 1/2020

Journal of Gastrointestinal Surgery 1/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.